A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01484496 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

839

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: Belimumab 200 mg SC
DRUG: Standard therapy

Sponsor

Human Genome Sciences Inc., a GSK Company

Collaborators

[object Object]